Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.

ABSTRACT: Objective was to describe the relationship between the number of sterile site infections and duration of neutropenia during the first four cycles of chemotherapy and the risk of recurrence and overall survival in children with newly diagnosed acute myeloid leukemia (AML). AAML0531 was a Children's Oncology Group randomized phase 3 clinical trial that included 1022 children with de novo AML. For this analysis, we focused on non-Down syndrome favorable and standard risk patients who completed at least 4 cycles of chemotherapy without recurrence or withdrawal during protocol therapy. Those receiving hematopoietic stem cell transplantation in first remission were excluded. Five hundred and sixty-nine patients were included; 274 (48.2%) were favorable risk. The median cumulative time with neutr

SUBMITTER: Sung L 

PROVIDER: S-EPMC4990479 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature